Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Cheri E. Klein"'
Autor:
Juki Ng, Ahmed Nader, Mohamad Shebley, Peter Noertersheuser, Megan A. Gibbs, Cheri E. Klein, Akshanth R. Polepally, Insa Winzenborg, Nael M. Mostafa
Publikováno v:
Clinical Pharmacokinetics
The clinical pharmacology of elagolix was extensively evaluated in clinical studies in healthy subjects and in women with endometriosis. Elagolix pharmacokinetics (PK) show significant population variability, however they are minimally affected by pa
Publikováno v:
Clinical Pharmacokinetics
Background Two pharmacokinetic/pharmacodynamic studies were conducted to evaluate the potential drug–drug interaction between elagolix, an oral gonadotropin-releasing hormone receptor antagonist, and an oral contraceptive (ethinylestradiol [EE] 0.0
Autor:
Ramona C. Rodila, Walid M. Awni, Gerd-Rüdiger Burmester, Charles Locke, Sandra L. Goss, Ziyi Jin, Hartmut Kupper, Cheri E. Klein
Publikováno v:
Clinical Therapeutics. 40:309-319
Methotrexate (MTX) and adalimumab are well-recognized treatments of rheumatoid arthritis (RA), the efficacy of which may be driven by intracellular polyglutamates (PGs). The aim of this analysis was to characterize MTX PG concentrations and adalimuma
Autor:
Walid M. Awni, John J. Brennan, Chih-Wei Lin, Nael M. Mostafa, Cheri E. Klein, Dennis Andress
Publikováno v:
Clinical Therapeutics. 40:242-251
Purpose The objective of the current analyses was to characterize the pharmacokinetic properties of atrasentan and the exposure-response relationships for the efficacy end point, urinary albumin to creatinine ratio (UACR), and the treatment-emergent
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 102:1683-1691
Context Elagolix is a nonpeptide, oral gonadotropin-releasing hormone (GnRH) antagonist being developed for sex-hormone-dependent diseases in women. Objective We evaluated the pharmacokinetics and pharmacodynamics of elagolix. Design, setting, and pa
Autor:
Eve C. Feinberg, Cheri E. Klein, Robert A. Feldman, Juki Ng, David F. Archer, Yi-Lin Chiu, Kristof Chwalisz, Charles E. Miller
Publikováno v:
The Journal of clinical endocrinology and metabolism. 105(3)
Context Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist recently approved for the treatment of endometriosis-associated pain and being developed for heavy menstrual bleeding associated with uterine fibroids. Objective The objecti
Autor:
Walid M. Awni, Rajeev M. Menon, Thomas Podsadecki, Cheri E. Klein, Yi-Lin Chiu, Sandeep Dutta
Publikováno v:
British Journal of Clinical Pharmacology. 81:929-940
Aims Paritaprevir is a direct acting antiviral agent for use as part of a multidrug hepatitis C virus infection treatment regimen. To characterize the pharmacokinetics, safety, and tolerability of paritaprevir and determine an optimal dosing regimen
Autor:
Ahmed Salem, Aksana K. Jones, Graham P. Taylor, Kristine B. Patterson, Angela M. Nilius, Cheri E. Klein, Marilia Santini-Oliveira
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:400-408
Lopinavir-ritonavir is frequently prescribed to HIV-1-infected women during pregnancy. Decreased lopinavir exposure has been reported during pregnancy, but the clinical significance of this reduction is uncertain. This analysis aimed to evaluate the
Autor:
Mohan Liu, Insa Winzenborg, Juki Ng, Ahmed Nader, Peter Noertersheuser, Akshanth R. Polepally, Nael M. Mostafa, Cheri E. Klein, Jacob F. Degner
Publikováno v:
Clinical pharmacokinetics. 57(10)
Elagolix is a novel, orally active, non-peptide, competitive gonadotropin-releasing hormone (GnRH) receptor antagonist in development for the management of endometriosis with associated pain and heavy menstrual bleeding due to uterine fibroids. The p
Autor:
Nathan S. Teuscher, Walid M. Awni, Richard J. Kelley, Emily O. Dumas, Colin J. Meyer, Cheri E. Klein
Publikováno v:
Clinical Pharmacology in Drug Development. 3:314-320
This study investigated the effect of food on the plasma pharmacokinetics of bardoxolone methyl, an antioxidant inflammation modulator, at a 20mg dose, and the dose proportionality of bardoxolone methyl pharmacokinetics from 20 to 80mg. It was a sing